Cortex Pharmaceuticals says that the FDA has turned thumbs down on its INDA for a Phase IIb trial of CX717 for ADHD after reviewing its animal toxicology studies. Cortex says its asking FDA officials to inactivate the INDA for that indication. Studies of CX717 will go ahead for respiratory depression and its Alzheimer's disease PET scan.
- see the releaseÂ from Cortex
Read more on:Â ADHD